Advertising Driven Press Release Distribution
Advertising Driven Press Release Distribution
From USD 1.6 billion in 2021, the global viral and non-viral vector manufacturing market size will reach USD 24.3 billion by 2027. It will exhibit an 18.45% CAGR during the forecast period.
Viral vectors are methods that molecular biologists frequently utilize to transfer genetic material into cells. It is a tool for transferring genes due to effective gene delivery, stable gene expression, and increased transfection efficacy. Nonviral vectors include naked DNA, particle-based vectors, and chemical-based vectors. Non-Viral vector, particularly Plasmid DNA plays a vital role in the healthcare industry owing to their use as a therapeutic agent in vaccine antigen generation and gene therapy.
Get a Free Sample Copy of this Research Report with Detailed TOC at https://www.vynzresearch.com/healthcare/viral-and-non-viral-vector-manufacturing-market/request-sample
Rising awareness of gene therapy, rising number of clinical trials, growing frequency of genetic abnormalities, technological development, surge in market demand for DNA therapeutics, increased research and development on cancer, and the spread of infectious diseases around the world are likely to propel the industry forward for viral and non-viral vector manufacturing market.
Nevertheless, the industry players are entering into strategic collaborations, M&A, and introducing new product along with expanding its geographical reach, thereby propelling the viral and non-viral vector manufacturing market forward.
In January 2021, Thermo Fisher Scientific Inc., one of the global leader in serving science, and Groupe Novasep SAS (Novasep), one of the leading provider of services and technologies to the life sciences industry, announced that Thermo Fisher has completed the acquisition of Henogen S.A., Novasep’s viral vector manufacturing business in Belgium, for approximately €725 million in cash.
Novasep’s viral vector production division provides biotechnology and major biopharma customers with contract manufacturing services for vaccines and therapies. Novasep’s viral vector company has two locations in Belgium: Seneffe and Gosselies. It has about 7,000 square metres of state-of-the-art clinical and commercial manufacturing capability.
The increased prominence of COVID-19 is anticipated to have a favorable impact on the market development of viral and non-viral vector manufacturing. The pandemic has offered attractive opportunities for viral vector and non-viral manufacturing sector participants. The COVID-19 viral vector-based vaccination (AZD1222) was developed by AstraZeneca (UK) and Janssen Pharmaceuticals (Belgium) in December 2020 and February 2021, respectively.
The development of these vaccines by prominent market participants has boosted demand for viral vectors, resulting in higher market revenue for viral vector producers.
Gene therapy, vaccinology, cell therapy, and other applications make up the global viral and non-viral vector manufacturing market. Gene therapy contributes to a significant share in the market as it is widely deployed to trat various kinds of disorders like sickle cell anemia, hemophilia, cystic fibrosis, Parkinson’s disease, Duchenne muscular dystrophy, etc.
Thus, the rising prominence of genetic disorders, increased awareness of gene therapy and chronic diseases will drive the market growth of gene therapy in the viral and non-viral vector manufacturing industry.
By Vector Type
North America contributes the largest share in the global viral and non-viral vector manufacturing market owing to the construction of manufacturing plants by the industry players, presence of many research centers that are involved in R&D to develop therapies will proliferate the growth in the region.
The market for cell therapies is growing substantially due to the rising number of companies participating in manufacturing ways for cell therapies, and to a significant extent for viral vector manufacturing procedures so as to meet the clinical requirements for late-phase clinical trials for viral vectors and non-viral vector manufacturing.
Explore More Upcoming & Published Reports by VynZ Research:
Global Flu Treatment Market – Analysis and Forecast (2021-2027)
Global Hand Sanitizer Market – Analysis and Forecast (2021-2027)
Global N95 Mask Market – Analysis and Forecast (2021-2027)
Global Facial/Surgical Mask Market – Analysis and Forecast (2021-2027)
Europe Electric Bus Market is Set to Reach 11,866 Units by 2024, Observing a CAGR of 32.9% during 2019–2024: VynZ Research
Testing, Inspection, and Certification Market for Electronics & Electrical Products Industry was USD 26 billion in 2020, registering a CAGR of 5.1% during the forecast period 2021-2027
Global Fuel Cell Electric Vehicle (FCEV) Market to reach USD 14.5 Billion at a CAGR of 37.5% during the forecast period
TIC Market for Food & Beverage Industry was USD 16 billion in 2020, registering a CAGR of 9% during the forecast period 2021-2027
Aseptic Pharma Processing Equipment Market will grow at a CAGR of 7.1% and Will Reach $115.75 BN by 2027